If you think the Hong Kong tech story is still just about consumer internet apps and ecommerce platforms, you are living in the past. The market is currently obsessing over "hard tech" and advanced manufacturing. Just look at the Global X China Core Tech ETF (3448.HK)—it's fundamentally a basket pointing away from software and straight into the arms of semiconductors and smart manufacturing. But let me tell you, when you actually look under the hood of this latest crop of innovators, it’s a bizarre mix of genuine AI infrastructure plays and the usual corporate theater of pivots and rebrands.

Let’s talk about the companies actually building the physical reality of this AI boom. LINGYI iTECH (1688.HK) just pulled off a massive dual-listing in June 2026. They are throwing everything at the wall—AI servers, robotics, and proudly touting their Nvidia supplier status. Their Q1 2026 revenue hit a record high, though their profits took a hit because building the future requires massive capital expenditure. Contrast that aggressive expansion with ASMPT (522.HK). Instead of chasing every shiny new toy, the packaging equipment giant is laser-focused. In June 2026, they dumped their non-core NEXX unit for USD 120 million to double down on advanced packaging. And it’s paying off beautifully—their Q1 2026 net profit surged. That’s exactly how you navigate a hardware supercycle.

Then you have the companies desperately trying to find a narrative. Veyong (3661.HK) saw its 2025 revenue plummet and is now pivoting to a "quality over scale" strategy in digital freight, which is usually just corporate speak for "we stopped bleeding money on useless growth." Meanwhile, Elite International (585.HK) is suddenly the talk of the town simply because a Gen-90 investor swooped in this April to push a new "finance plus entertainment" strategy, sending shares on a wild upward ride recently. And let's not forget the quieter side of the new economy—Giant Biogene (6682.HK) has been remarkably silent lately, seemingly sitting out the current cycle of hype entirely.

The only other sector showing real validation right now is biotech dealmaking. Laekna (3952.HK) secured a massive licensing deal with Vasque Bio this June for its LAE118 asset, with potential milestones topping USD 517 million. That’s actual, tangible validation from overseas players, not just a buzzword dropped in an annual report.

The bottom line? The era of blindly buying a basket of "tech" stocks and going to sleep is over. You either have the hardware and patents the AI revolution actually needs, or you’re just making noise. Do your homework, and ignore the press releases.